Literature DB >> 31435197

Use of Vedolizumab for the Treatment of Crohn's Disease.

Brian Bressler1.   

Abstract

Entities:  

Year:  2019        PMID： 31435197      PMCID： PMC6696600     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.

Authors:  Brian G Feagan; Karen Lasch; Trevor Lissoos; Charlie Cao; Abigail M Wojtowicz; Javaria Mona Khalid; Jean-Frédéric Colombel
Journal:  Clin Gastroenterol Hepatol       Date:  2018-05-29       Impact factor: 11.382

2.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

Authors:  Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer
Journal:  Gastroenterology       Date:  2014-05-21       Impact factor: 22.682

3.  Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.

Authors:  Mindy Cw Lam; Brian Bressler
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

5.  The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Authors:  Jean-Frédéric Colombel; Bruce E Sands; Paul Rutgeerts; William Sandborn; Silvio Danese; Geert D'Haens; Remo Panaccione; Edward V Loftus; Serap Sankoh; Irving Fox; Asit Parikh; Catherine Milch; Brihad Abhyankar; Brian G Feagan
Journal:  Gut       Date:  2016-02-18       Impact factor: 23.059

6.  Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

Authors:  Stefan Schreiber; Axel Dignass; Laurent Peyrin-Biroulet; Greg Hather; Dirk Demuth; Mahmoud Mosli; Rebecca Curtis; Javaria Mona Khalid; Edward Vincent Loftus
Journal:  J Gastroenterol       Date:  2018-06-04       Impact factor: 7.527
  6 in total
  2 in total

Review 1.  A review of the therapeutic management of Crohn's disease.

Authors:  Aditi Kumar; Alexander Cole; Jonathan Segal; Philip Smith; Jimmy K Limdi
Journal:  Therap Adv Gastroenterol       Date:  2022-02-17       Impact factor: 4.409

2.  Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

Authors:  Siddharth Singh; M Hassan Murad; Mathurin Fumery; Rocio Sedano; Vipul Jairath; Remo Panaccione; William J Sandborn; Christopher Ma
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.